Welcome to the final set of tweetorials from @GoggleDocs A look at some of the interesting trials on hypertension from #ESCCongress
First up we're giving you some SSaSS!
No, not that, we are talking about salt and salt substitution!
What is the recommendation for daily sodium intake according to @American_Heart for healthy individuals?
The AHA recommends no more than 2300mgs salt per day and no more than 1500mgs in HTN…though many eat more than this…
So putting that into teaspoons of salt… 1/4 teaspoon salt = 575 mg sodium 1/2 teaspoon salt = 1,150 mg sodium 3/4 teaspoon salt = 1,725 mg sodium
1 teaspoon salt = 2,300 mg sodium
Low sodium diets are recommended in CCF, CKD and also been found to aid BP reduction …. but what about salt substitution…
Salt substitution aims to reduce sodium intake by replacing sodium with potassium salts
➡️ also has an added benefit (for some) of increasing potassium intake …one issue.. the more the potassium chloride used the more metallic the taste
So there needs to be balance with amount of potassium and acceptability...
In this study, different percentages of KCl were tested to assess acceptability… upto 30% KCl substitution was reasonably acceptable.
The impact of this salt substitution on BP has been shown with metanalyses showing 5.5mmHg SBP and 2.4mmHg in DBP in hypertensive individuals…with benefit even seen in normotensive people
This study enrolled 20,995 people from 600 villages across rural China over 5 years to either 100% Nacl or 75% NaCl/25% KCl substitution
Inclusions
History of stroke or >60yrs old
History of ⬆️BP (>/= 160mmHg if untreated, >/= 140 if treated)
Exclusions
Contraindication to salt substitution, K+ sparing diuretic use, K+ supplement use or serious kidney disease, likely to live <6/12 or ate mostly outside the house
Primary outcome – stroke 🧠
Secondary outcome – MACE (non-fatal stroke, non-fatal ACS or CV mortality)🫀 and all cause mortality ☠️
Key safety outcome – hyperkalaemia (and also sudden death)
A look at the baseline characteristics 👀
Interesting to see ⬆️ percentage with uncontrolled hypertension, ⬇️ACEi use, M=F split and relatively ⬇️diabetes population
Nice data showing BP reduction over this trial period (mean FU 4.74yrs) and as expected reduced sodium excretion
But we know this from previous trials and data… what about the important CV results….
Primary Outcome
🧠⬇️13% rate of fatal or non-fatal stroke p = 0.006 [29.14 vs 33.65 events/1000 patient yrs] - no difference in non-fatal stroke
Secondary Outcomes
13% ⬇️MACE p<0.001
12% ⬇️Death from any cause p<0.001
13% ⬇️Death from vascular causes
30%⬇️Non-fatal ACS
Importantly, no increased risk of hyperkalaemia 👍🏽
Some impressive findings of reduced stroke and further reductions in all cause mortality, death from vascular causes and non-fatal ACS with no real significant adverse events....
Rural Chinese population - can this be generalisable?
Potassium was not monitored serially throughout the trial (so hyperkalaemia potentially might have been missed) - though no major adverse event differences
Do we need more data?
Can we generalize this to other areas?
Is this something that we should be advising now?
What does this mean for practical application?
Is this a chance for a population based intervention?
That's for you to answer. Based on this trial, I would...
So I ask you again… is this study worth its salt?
That’s all for now.
But do return as we continue our journey and STEP further into rural China with another blood pressure trial!
1) Welcome to a 🆕 #accredited #tweetorial on #Albuminuria: The Canary in the Coal Mine of #Kidney and #Cardiorenal #Disease. Our returning expert author is the wonderful teacher Edgar V. Lerma 🇵🇭 @edgarvlermamd
#Cardiorenal #Nephpearls #nephtwitter #FOAMed #CardioTwitter
2) The program is intended for #HCPs & is supported by an independent educational grant from Bayer. Statement of accreditation and faculty disclosures at . Follow this 🧵for 0.75hr 🆓 CE/#CMEcredit--all delivered right here on X!cardiometabolic-ce.com/disclosures/
3) A canary in a coal mine is an advanced warning of danger. The term originates from when miners carried caged canaries while at work; if there was any methane or carbon monoxide in the mine, the canary would die before the levels of the gas reached those hazardous to humans.
1) Welcome to a 🆕#accredited #tweetorial on the challenges clinicians face when managing #venous #thromboembolism in patients with #cancer: cancer-associated thrombosis or #CAT. Our expert faculty is #shematologist Jean Connors MD @connors_md at @BrighamWomens & @DanaFarber.
2a) The program is intended for #healthcare professionals & supported by an independent educational grant from Anthos Therapeutics. Statement of accreditation & faculty disclosures at .cardiometabolic-ce.com/disclosures/
2b) Earn 0.5 hr 🆓CE/#CME by following this 🧵 & follow us for more expert-authored #MedEd. #FOAMed #ONCSM @MedTweetorials #CardioTwitter #cvCoag
🚨See prior programs in this area, still available for MedEd credit, at .cardiometabolic-ce.com/category/antit…
1) Welcome to the next installment of our #MedEd series on the potential for selective inhibitors of coagulation Factor XI or XIa (#FXI/#XIa) for therapeutic anticoagulation. Catch up with us by viewing & earn 🆓CE/#CMEcredit if you haven't already!cardiometabolic-ce.com/antithrombotic…
2) That prior program shared and explained the results of the #LBCT data from #AZALEA_TIMI_71 at #AHA23. Lots has happened in the #FXI world since then, so it's time revisit and recap.
3) It's always an honor when expert #cardiologist and incredible #researcher #educator C. Michael Gibson @CMichaelGibson pens an #accredited #tweetorial for us, but in particular we welcome his view on the most recent data and evolving thinking about #FXI inhibition.
1) Welcome to a 🆕#LIVE #accredited #tweetorial posted from #Toronto and #WSC2023, where we have just seen top-line results of #ANNEXa_I, the FIRST randomized comparison between #andexanet_alfa & usual care in pts with anti-#FXa #DOAC-associated #ICH.
2) Our expert author is #ANNEXa_I investigator Ashkan Shoamanesh MD @Ash_Shoamanesh, #Stroke #Neurologist @HamHealthSci, Assoc Prof @McMasterU, & Director of Hemorrhagic Stroke Research Program & Scientist @PHRIresearch #FOAMed #FOAMcc #neurotwitter #cardiotwitter #MedEd
3) This program is supported by an independent educational grant from AstraZeneca. Statement of accreditation & faculty disclosures at . FOLLOW @cardiomet_ce for more expert-led 🆓CE/#CME delivered wholly on Twitter!cardiometabolic-ce.com/disclosures/
1a) Welcome to a 🆕#accredited tweetorial on Analyzing Safety Data for #siRNA for Lowering #LDL-C and #Lp(a). Our expert faculty is James A. Underberg, MD, MS, FACPM, FACP, MNLA @lipiddoc
#Cardiotwitter #FOAMed
1b) @lipiddoc is a #lipidologist🩺🧬@nyulangone @NYUCVDPrevent. He is President of the Foundation of @nationallipid, Past-President of both @nationallipid AND @LipidBoard, and is Director of @BHLipidClinic. @cardiomet_CE is proud to welcome @lipiddoc as new faculty!
2) This presentation was originally delivered by @lipiddoc at an accredited satellite symposium at @nationallipid's June 2023 congress. He shared the podium there with lipidology & #preventive #cardiology experts @alanbrownmd, @jpenamd, & @NP_ltl_a.
@MedTweetorials
1) Welcome to a 🆕#accredited tweetorial on Recent Advances in the Risk Assessment in Patients with Hyperlipidemia: Enhancing Precision and Reliability. Our expert faculty is Dr Nataliya Pyslar @NP_ltl_a, #Cardiologist& Lipid Specialist @CookCtyHealth.
#Cardiotwitter #FOAMed
2) This presentation was originally delivered by @NP_ltl_a at an accredited satellite symposium at @nationallipid's June 2023 congress. She shared the podium there with lipidology & #preventive #cardiology experts @alanbrownmd, @jpenamd, & @lipiddoc.
@MedTweetorials
3a) The symposium and this tweetorial were supported by an unrestricted educational grant from Novartis. Statement of accreditation & faculty disclosures at .cardiometabolic-ce.com/disclosures/